EGLN1: Egl nine homolog 1
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins.
- Drugs that act on it: 3
- Approved: 1
- In phases 1 to 3: 2
- Sponsors: 3
- Type: Protein
Who Is On It, and How Far Along
Every drug ChEMBL records acting on EGLN1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Egl nine homolog 1 inhibitor.| Vadadustat | Approved | Akebia Therapeutics | Small molecule | Inhibitor | — | 3 | Boxed warning |
| Enarodustat | Phase 3 | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Small molecule | Inhibitor | — | 5 | — |
| Molidustat | Phase 2 | Bayer | Small molecule | Inhibitor | — | 1 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Erythrocytosis, familial, 3
- 0.73
- Anemia
- 0.60
- Neurodegenerative disease
- 0.48
- Autosomal dominant secondary polycythemia
- 0.47
- Chronic renal failure syndrome
- 0.37
- Gastric cancer
- 0.34
- Stage 5 chronic kidney disease
- 0.33
- Triple-negative breast carcinoma
- 0.33
- Kidney disorder
- 0.26
- Aplastic anemia
- 0.26
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- EGLN1
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5697, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9GZT9, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets